Skip to search formSkip to main contentSkip to account menu

velaglucerase alfa 400 UNT Injection [Vpriv]

Known as: VELAGLUCERASE ALFA 2.5 mg in 1 mL INTRAVENOUS INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [VPRIV], VPRIV 400 UNT Injection 
National Institutes of Health

Related topics

Related topics

8 relations
InjectionPolysorbate 20SucroseVpriv

Broader (1)

velaglucerase alfa 400 UNT Injection

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Maladie de Gaucher : cohorte française de 89 patients traités par vélaglucérase alpha
2013
2013
Safety and efficacy of velaglucerase alfa replacement therapy for patients with type 1 Gaucher disease
Gaucher disease is a multisystem disorder caused by deficiency of β-glucocerebrosidase. Exogenously delivered enzyme replacement… 
2011
2011
Recent advances in treatment approaches to Gaucher disease.
Gaucher disease is inherited as an autosomal recessive disorder. The absence of β-glucocerebrosidase whose purpose is to cleave… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)